» Articles » PMID: 35523497

End-of-life Care in Cancer Patients: How Much Drug Therapy and How Much Palliative Care? Record Linkage Study in Northern Italy

Overview
Journal BMJ Open
Specialty General Medicine
Date 2022 May 6
PMID 35523497
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Investigating end-of-life use of anticancer drugs and of palliative care services.

Design: Population based cohort linked to mortality registry and administrative databases.

Setting: Emilia-Romagna Region (Northern Italy).

Participants: 55 625 residents who died of cancer between 2017 and 2020.

Primary And Secondary Outcome Measures: Multivariate analyses were carried out to assess the relationship between cancer drug therapy and palliative care services, and their association with factors related to tumour severity.

Results: In the last month of life, 15.3% of study population received anticancer drugs (from 12.5% to 16.9% across the eight Local Health Authorities-LHA) and 40.2% received palliative care services (from 36.2% to 43.7%). Drug therapy was inversely associated with receiving palliative care services within the last 30 days (OR 0.92, 95% CI 0.87 to 0.97), surgery within the last 6 months (OR 0.59, 95% CI 0.52 to 0.67), aggressive tumours (OR 0.88, 95% CI 0.84 to 0.93) and increasing age (OR 0.95, 95% CI 0.95 to 0.95). Drug therapy was more likely among those with haematologic tumours (OR 2.15, 95% CI 2.00 to 2.30) and in case of hospital admissions within the last 6 months (OR 1.63, 95% CI 1.55 to 1.72). Palliative care was less likely among those with haematologic compared with other tumours (OR 0.52, 95% CI 0.49 to 0.56), in case of surgery (OR 0.44, 95% CI 0.39 to 0.49) or hospital admissions (OR 0.70, 95% CI 0.67 to 0.72) within the last 6 months, if receiving anticancer drugs during the last 30 days (OR 0.90, 95% CI 0.85 to 0.94) and for each year of increasing age (OR 0.99, 95% CI 0.99 to 0.99). Palliative care was more likely in the presence of aggressive tumours (OR 1.12, 95% CI 1.08 to 1.16).

Conclusion: Use of anticancer drugs and palliative care in the last month of life were inversely associated, showing variability across different LHAs. While administrative data have limits, our findings are in line with conclusions of other studies.

Citing Articles

Scoping Review of International Experience of a Dedicated Fund to Support Patient Access to Cancer Drugs: Policy Implications for Thailand.

Luksameesate P, Nerapusee O, Patikorn C, Anantachoti P Int J Health Policy Manag. 2024; 13:7768.

PMID: 39620551 PMC: 11607595. DOI: 10.34172/ijhpm.2023.7768.


Anticancer therapy at end-of-life: A retrospective cohort study.

Singh J, Stensvold A, Turzer M, Grov E Acta Oncol. 2024; 63:313-321.

PMID: 38716486 PMC: 11332458. DOI: 10.2340/1651-226X.2024.22139.


PALLiative care in ONcology (PALLiON): A cluster-randomised trial investigating the effect of palliative care on the use of anticancer treatment at the end of life.

Hjermstad M, Pirnat A, Aass N, Andersen S, Astrup G, Dajani O Palliat Med. 2024; 38(2):229-239.

PMID: 38193250 PMC: 10865754. DOI: 10.1177/02692163231222391.


Systemic Anticancer Treatment Near the End of Life: a Narrative Literature Review.

Geyer T, Le N, Groissenberger I, Jutz F, Tschurlovich L, Kreye G Curr Treat Options Oncol. 2023; 24(10):1328-1350.

PMID: 37501037 PMC: 10547806. DOI: 10.1007/s11864-023-01115-x.


Pattern of care of brain tumor patients in the last months of life: analysis of a cohort of 3045 patients in the last 10 years.

Pace A, Belleudi V, Tanzilli A, Villani V, Poggi F, Benincasa D Neurol Sci. 2023; 44(8):2897-2902.

PMID: 36882595 DOI: 10.1007/s10072-023-06722-y.


References
1.
Brom L, Onwuteaka-Philipsen B, Widdershoven G, Pasman H . Mechanisms that contribute to the tendency to continue chemotherapy in patients with advanced cancer. Qualitative observations in the clinical setting. Support Care Cancer. 2015; 24(3):1317-25. PMC: 4729795. DOI: 10.1007/s00520-015-2910-7. View

2.
Hui D, Park M, Liu D, Paiva C, Suh S, Morita T . Clinician prediction of survival versus the Palliative Prognostic Score: Which approach is more accurate?. Eur J Cancer. 2016; 64:89-95. PMC: 4969216. DOI: 10.1016/j.ejca.2016.05.009. View

3.
Rodriguez M, DeJesus A, Cheng L . Use of chemotherapy within the last 14 days of life in patients treated at a comprehensive cancer center. JAMA Intern Med. 2014; 174(6):989-91. DOI: 10.1001/jamainternmed.2014.1001. View

4.
Crawford G, Dzierzanowski T, Hauser K, Larkin P, Luque-Blanco A, Murphy I . Care of the adult cancer patient at the end of life: ESMO Clinical Practice Guidelines. ESMO Open. 2021; 6(4):100225. PMC: 8411064. DOI: 10.1016/j.esmoop.2021.100225. View

5.
Jang R, Caraiscos V, Swami N, Banerjee S, Mak E, Kaya E . Simple prognostic model for patients with advanced cancer based on performance status. J Oncol Pract. 2014; 10(5):e335-41. DOI: 10.1200/JOP.2014.001457. View